Phosphagenics starts morphine cream trial

By Elaine Rigoli

Tampa, Fla., May 8 - Phosphagenics Ltd. has started a phase 2a clinical trial of its transdermal morphine cream, TPM-01/Morphine, to investigate the efficacy, absorption and metabolism of morphine administered using Phosphagenics' novel transdermal carrier TPM-01.

In the trial, doses of morphine will be examined in 48 healthy male volunteers ages 18 to 49 years old. Volunteers will be randomly assigned into a dose group and either receive active treatment or a placebo treatment in a double-blinded manner.

The efficacy of Phosphagenics' transdermal morphine in producing the well-recognized effects of morphine in humans, such as changes in pupil size and decreased response to painful stimuli, will be measured, the company said in a news release.

Phosphagenics' product is a non-invasive, patient-friendly gel or cream that delivers morphine through the skin into the bloodstream, the release said.

Preliminary results are expected during the third quarter of 2006.

Based in Melbourne, Australia, Phosphagenics is a pharmaceutical and nutraceutical company encompassing drug delivery, drug enhancement and active ingredients for the nutraceutical industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.